Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06037564
Other study ID # B-free trial - Stage 1
Secondary ID
Status Enrolling by invitation
Phase Phase 4
First received
Last updated
Start date November 13, 2023
Est. completion date December 2027

Study information

Verified date November 2023
Source Insel Gruppe AG, University Hospital Bern
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of a booster-free regimen including DOR/DTG/3TC among HIV-suppressed PLWH with previous virological failure. The key secondary objectives are i) to determine whether switching to DOR / DTG / 3TC leads to lower burden of DDI compared to continuing a booster-containing regimen, and ii) to assess changes in patient perception on treatment acceptability and satisfaction, as well as health-related quality of life after a switch to booster-free ART. Qualitative sub-study: Qualitative objectives will be met using semi-structured interviews. Thirty people (15 from the intervention arm, 15 from the control arm) will be interviewed twice, at week 0 and week 48. Additional 15 individuals from the observational cohort will be interviewed once. Interviews will take place following study visits and performed using semi-structured guides. The guide for the interviews at week 48 will be based on results from analyses of the interviews conducted at week 0.


Description:

Life expectancy of persons living with HIV on antiretroviral therapy (ART) is increasing and drug-drug interactions (DDI) with co-medications are becoming a major concern. Individuals who previously experienced virological failure are at risk of DDI as they are generally treated with ritonavir- or cobicistat-boosted ART. The high potency as well as the favorable safety and pharmacokinetic profile of new antiretroviral drugs, including dolutegravir (DTG) and doravirine (DOR), support their evaluation as part of un-boosted therapy for individuals with a history of virological failure. In this adaptive trial within the Swiss HIV Cohort Study (SHCS) and partner clinics in the Netherlands, the investigators aim to evaluate the efficacy and acceptability of the booster-free regimen DOR/DTG/3TC for treatment-experienced individuals.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 210
Est. completion date December 2027
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria - Informed consent as documented by signature - Registered in the SHCS or ATHENA cohort study - Age =18 years - Documented HIV-1 infection - On ART including a pharmacological booster (ritonavir or cobicistat) and at least 2 drugs from classes other than NRTI (e.g. non-nucleoside reverse transcriptase inhibitor, integrase-inhibitor, protease inhibitor or entry inhibitor) - History of ART change due to virological failure - HIV-RNA <50 cp/mL at screening and for at least 24 weeks before screening, one blip with less than 200 cp/mL allowed Exclusion criteria - Creatinine clearance <30mL/min, calculated using the CKD-EPI formula - Known hypersensitivity, allergy, or intolerance to DOR, DTG, or 3TC - Presence of major drug resistance mutations against DTG or DOR. DTG (G118R, G140R, Q148H, Q148K, Q148R, R263K) or DOR (V106A, Y188L, F227C, F227L, M230L, Y318F) according to IAS-USA. Patients without available resistance testing should not be excluded if no resistance to DTG and/or DOR is assumed based on ART history. - Concomitant use of drugs that decrease DTG or DOR blood concentrations - Chronic hepatitis B infection, defined as a positive hepatitis B surface antigen (HBsAg) at the screening visit - Women who are pregnant or breast-feeding. Women of childbearing potential (women who are not surgically sterilized / hysterectomised and / or post-menopausal for longer than 2 years must have a negative pregnancy test at screening). - Participation in another ART intervention study within the 30 days preceding and during the present study. Qualitative sub-study The same inclusion and exclusion criteria as those listed above will be applied. Fifteen persons who were excluded from the trial based on the exclusion criteria above will be recruited for qualitative interviews. In addition to the criteria mentioned above, individuals who are not fluent in German or French will be excluded from the qualitative sub-study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DOR/DTG/3TC
Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.

Locations

Country Name City State
Switzerland University Hospital Basel Basel
Switzerland Inselgruppe AG Bern
Switzerland University Hospital Geneva Geneva
Switzerland University of Lausanne Hospitals Lausanne
Switzerland Lugano Regional Hospital Lugano Lugano
Switzerland Cantonal Hospital of St. Gallen St. Gallen
Switzerland University Hospital Zürich Zürich

Sponsors (3)

Lead Sponsor Collaborator
Insel Gruppe AG, University Hospital Bern Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, University of Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in CD4 cell count from baseline to week 48 The CD4 cell counts will be obtained at baseline and week 48. Week 0 and 48
Other Change in metabolic variables (cholesterol) Change in total cholesterol Week 0 and 48
Other Change in metabolic variables (low density lipoprotein) Change in low density lipoprotein-cholesterol Week 0 and 48
Other Change in metabolic variables (high density lipoprotein) Change in high density lipoprotein-cholesterol Week 0 and 48
Other Change in metabolic variables (triglycerides) Change in triglycerides Week 0 and 48
Other Change in body weight Change in body weight from baseline to week 48 Week 0 and 48
Other Change in BMI Change in BMI from baseline to week 48 Week 0 and 48
Other Change in renal function, assessed by glomerular filtration rate Changes in glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) from baseline to week 48 Week 0 and 48
Other Change in renal function, assessed by urine protein-to-creatinine ratio Change in renal function (glomerular filtration rate) using the urine protein-to-creatinine ratio from baseline to week 48 Week 0 and 48
Other Proportion of patients with new drug-related CNS symptom(s) at week 4 Proportion of patients with new drug-related central nervous system (CNS) symptom(s) at the 4 week visit. Week 4
Other Proportion of patients with new drug-related CNS symptom(s) reporting new drug-related CNS symptom(s) at any time point between baseline and week 48. Occurrence of CNS Adverse Events (AEs) in patients new to DTG Week 0 to 48
Other Proportion of patients with a Serious Adverse Event (SAE) at any time point Proportion of patients with a SAE, graded using the Division of AIDS table for grading AEs at any time point. Week 0 to 48
Primary Loss of viral suppression Difference in the proportion of individuals with an HIV-RNA =50 cp/mL at 48 weeks between the treatment arms. Week 48
Secondary Changes in DDI score from week 0 to 48 Using the University of Liverpool Drug Database (https://www.hiv-druginteractions.org/), the prescribed ART and co-medications will be categorized as red flag (3 points) for severe DDIs when co-administration is contraindicated, amber flag (2 points) for potential clinically significant DDIs manageable by dose adjustment or clinical monitoring, yellow flag (1 point) for DDIs of weak clinical relevance with no need of a priori dosage adjustment or monitoring, and a green flag (0 points) for no interactions. Amber flag DDIs will be downgraded to 1 point if there is evidence that the DDI was managed correctly (i.e. DTG administered 2 hours before or 6 hours after taking divalent cations). The sum of all points at visit 6, week 48 will be compared to baseline. Week 0 and 48
Secondary Patient report outcomes concerning changes in treatment satisfaction between baseline and 48 weeks, as determined using the HIV Treatment Satisfaction Questionnaire HIVTSQc (change version). The investigators will assess changes in treatment satisfaction between week 0 and 48 using the validated HIV Treatment Satisfaction Questionnaire HIVTSQc (change version). Week 0 to 48
Secondary Proportion of patients experiencing confirmed virological failure Proportion of patients experiencing confirmed virological failure, defined as 2 consecutive plasma HIV viral loads =200 copies/mL Week 48
Secondary Proportion of individuals detected with new drug resistance Proportion of individuals experiencing impairment / loss of future drug options throughout the study period, defined as new detection of resistance-associated mutations against DOR, DTG, 3TC (intervention-arm) or against the components of the ART regimen that the virus was considered to be sensitive to at randomization (based on historic resistance testing or treatment history; control-arm). Week 0 to 48
Secondary Proportion of individuals with any moderate (orange flag) or severe (red flag) DDI Proportion of individuals with any moderate (orange flag) or severe (red flag) DDI at any study visit between baseline and week 48, based on the results from the Liverpool drug interaction database (www.hiv-druginteractions.org). Week 0 to 48
Secondary Proportion of patients with DDI leading to suboptimal management of comorbidities Proportion of patients with DDI leading to suboptimal management of comorbidities between baseline and week 48, as reported by the cohort physician. Week 0 and 48
Secondary Patient report outcomes concerning differences in quality of life between both groups at week 48 assessed by the World Health Organization Quality-of-Life- HIV Bref (WHOQOL-HIV BREF) questionnaire Differences in quality of life between both groups at week 48, assessed using the World Health Organization Quality-of-Life- HIV Bref (WHOQOL-HIV BREF) questionnaire Week 48
Secondary Patient report outcomes concerning differences in treatment satisfaction between both groups assessed by HIV Treatment Satisfaction Questionnaires The investigators will assess the differences in treatment satisfaction between both groups at week 48, as determined using the validated HIV Treatment Satisfaction Questionnaires HIVTSQ. Week 48
Secondary Proportion of individuals reporting depression assessed by Patient Health Questionnaire-9 Depression will be assessed at baseline and week 48, assessed using the Patient Health Questionnaire-9 (PHQ-9) Week 0 and 48
Secondary Changes in intact proviral HIV-DNA levels Changes in intact proviral HIV-DNA levels in peripheral blood mononuclear cells (PBMCs) between baseline and week 48. Stored PBMC samples will be used to determine HIV-DNA levels by a digital droplet PCR (ddPCR) assay using the RAINDANCE system. Week 0 to 48
Secondary Proportion of individuals who develop a detectable HBV viral load Proportion of individuals with a positive anti-HBc and negative anti-HBs ("anti-HBc alone") who develop a detectable HBV viral load (>50 IU/mL) at weeks 24 and 48. Weeks 24 and 48
Secondary Cumulative cost of all ART drugs used The 48-weeks cumulative cost of the received ART regimen will be calculated using prices published by the Federal Office of Public Health (https://www.spezialitaetenliste.ch/ShowPreparations.aspx). Week 0 to 48
Secondary Perception of the trial and/or of HIV-related research in general assessed by qualitative interviews in a subset of approximately 30 trial participants Perception of the trial and/or of HIV-related research in general. Week 0 and 48
Secondary Acceptability conditions of participation in the trial assessed by qualitative interviews in a subset of approximately 30 trial participants Acceptability conditions, understood as all barriers and facilitators to be involved in a trial. Week 0 and 48
Secondary Needs regarding the booster-free regimen or regarding ART in general assessed by qualitative interviews in a subset of approximately 30 trial participants Needs regarding the booster-free regimen or regarding ART in general for participants included in the observational cohort. Week 0 and 48
Secondary Expectations regarding the booster-free regimen or regarding ART in general assessed by qualitative interviews in a subset of approximately 30 trial participants Expectations regarding the booster-free regimen or regarding ART in general for participants included in the observational cohort. Week 0 and 48
Secondary Perspectives on how the participants' current and anticipated needs can be assessed by qualitative interviews in a subset of approximately 30 trial participants Perspectives on how the participants' current and anticipated needs can be addressed by research. Week 0 and 48
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2